News Sentiment

LRMR sentiment intelligence

Larimar Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.28 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+31.3% over one week, +23.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 31.3% Price confirming higher
Trend fit Trend inactive 23.3% over four weeks
Fair value -12.5% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 37
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
TradingView 8
Stock Titan 7
GlobeNewswire 4
simplywall.st 4
Stocktwits 3
StocksToTrade 3
Moomoo 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 13
Regulatory and legal 8
Analyst action 5
Deals and strategy 3
Balance sheet 2
Macro sensitivity 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 63
Market source Direct company coverage

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Larimar Therapeutics (LRMR) has submitted the initial module of its Biologics License Application (BLA) to the U.S. FDA for accelerated approval of its Nomlabofusp therapy, targeting Friedreich's ataxia. The therapy showed positive results in an open-label study, and the FDA conf

Tone
Positive 64/100
Event
Earnings
Published
15 Jul 2026 10:43
Source
Market source
FinancialContent Direct company coverage

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR | FinancialContent

Pomerantz LLP is investigating potential securities fraud claims against Larimar Therapeutics, Inc. (NASDAQ: LRMR) on behalf of investors. The investigation stems from two instances where the company's stock price fell significantly after announcing "positive" data from a Friedre

Tone
Negative 40/100
Event
Regulatory and legal
Published
14 Jul 2026 21:15
Source
FinancialContent
TradingView Direct company coverage

Price to earnings forward of Larimar Therapeutics, Inc. – LS:A2P5PP

This article displays the "Price to earnings forward" for Larimar Therapeutics, Inc. (A2P5PP) on the TradingView platform. It shows that the market for this stock is closed and there have been no trades for this specific financial metric. The content primarily focuses on the disp

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 01:10
Source
TradingView
Stocktwits Direct company coverage

Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy

Larimar Therapeutics Inc. (LRMR) has priced an upsized $100 million stock offering after its shares surged over 60% following the FDA granting Breakthrough Therapy Designation to its frataxin protein replacement therapy, Nomlabofusp, for Friedreich’s ataxia. The funds will suppor

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 19:42
Source
Stocktwits
Moomoo Direct company coverage

Thomas Hamilton Bought 6.1% More Shares In Larimar Therapeutics

The article reports that Thomas Hamilton increased his holdings in Larimar Therapeutics by 6.1%. This acquisition suggests a positive outlook on the company's future prospects from a notable investor.

Tone
Positive 66/100
Event
Deals and strategy
Published
10 Jul 2026 18:09
Source
Moomoo
PR Newswire Direct company coverage

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

Pomerantz LLP is investigating claims against Larimar Therapeutics, Inc. (NASDAQ: LRMR) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows two significant stock price drops after the company disclosed instances of anap

Tone
Negative 28/100
Event
Regulatory and legal
Published
09 Jul 2026 19:57
Source
PR Newswire
Investing.com India Direct company coverage

Larimar Therapeutics stock jumps on insider purchase By Investing.com

Larimar Therapeutics Inc (NASDAQ:LRMR) shares jumped 15.5% after director Thomas Edward Hamilton purchased 50,000 shares of common stock. The insider acquisition, valued at approximately $166,890, signals confidence in the biopharmaceutical company from a board member. Hamilton n

Tone
Positive 77/100
Event
Deals and strategy
Published
09 Jul 2026 16:10
Source
Investing.com India
TradingView Direct company coverage

Enterprise value to revenue forward of Larimar Therapeutics, Inc. – SWB:ZA71

This article provides financial information for Larimar Therapeutics, Inc. (SWB:ZA71) available on TradingView, specifically focusing on its enterprise value to revenue forward. It indicates the stock is traded on the Stuttgart Stock Exchange and details various financial and res

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 23:41
Source
TradingView
Market source Direct company coverage

LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000

Shares of Larimar Therapeutics, Inc. (LRMR) rose 3% after hours following director Thomas E. Hamilton's purchase of 50,000 shares for approximately $167,000. This insider buying comes as H.C. Wainwright initiated 'Buy' coverage with a $10 price target, anticipating a commercial l

Tone
Positive 71/100
Event
Analyst action
Published
08 Jul 2026 22:41
Source
Market source
Stock Titan Direct company coverage

Larimar Therapeutics (LRMR) director purchases 50,000 common shares

Larimar Therapeutics director Thomas Edward Hamilton purchased 50,000 common shares in an open-market transaction at a weighted average price of $3.3378 per share. Following this acquisition, Hamilton now directly holds 714,798 common shares and indirectly holds 159,433 shares th

Tone
Positive 73/100
Event
Deals and strategy
Published
08 Jul 2026 19:41
Source
Stock Titan
Stock Titan Direct company coverage

If You Invested $1,000 in Larimar Therapeutics Inc (LRMR)

This article analyzes the historical performance of investing $1,000 in Larimar Therapeutics Inc (LRMR) over 1, 5, and 10 years, detailing the returns and compound annual growth rates. It also provides an overview of Larimar Therapeutics, a clinical-stage biotechnology company fo

Tone
Neutral 50/100
Event
Macro sensitivity
Published
04 Jul 2026 01:40
Source
Stock Titan
Insider Monkey Direct company coverage

Here’s What Citi Thinks About Larimar Therapeutics (LRMR)

Citi analyst Samantha Semenkow maintained a Buy rating on Larimar Therapeutics (LRMR) with a $14 price target, citing optimism surrounding its lead drug Nomlabofusp for Friedreich’s ataxia. The bullish outlook is driven by upcoming catalysts including new clinical data and a plan

Tone
Positive 76/100
Event
Analyst action
Published
03 Jul 2026 09:13
Source
Insider Monkey
Market source Direct company coverage

LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns

Shares of Larimar Therapeutics (LRMR) held steady despite recent weakness driven by drug safety concerns, as Wall Street analysts maintained bullish ratings. H.C. Wainwright initiated coverage with a 'Buy' rating and a $10 price target, citing the company's regulatory progress fo

Tone
Neutral 50/100
Event
Analyst action
Published
02 Jul 2026 20:32
Source
Market source
TradingView Direct company coverage

Price to book forward of Larimar Therapeutics, Inc. – LS:A2P5PP

This article provides financial information for Larimar Therapeutics, Inc. under the stock symbol LS:A2P5PP. It specifically highlights the "Price to book forward" metric. The content appears to be a financial data page from TradingView, indicating that the market is currently cl

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 15:39
Source
TradingView
GuruFocus Direct company coverage

LRMR Assumed by HC Wainwright & Co. -- Rating Set to Buy

HC Wainwright & Co. has initiated coverage on Larimar Therapeutics (LRMR) with a Buy rating and a price target of $10.00, citing confidence in the company's potential despite its current low profitability and growth metrics. Larimar Therapeutics, a clinical-stage biotechnology co

Tone
Positive 72/100
Event
Analyst action
Published
02 Jul 2026 13:12
Source
GuruFocus
TradingView Direct company coverage

Price to book forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR

This page from TradingView displays the "Price to book forward" metric for Larimar Therapeutics, Inc. (NASDAQ: LRMR). The content indicates the company's financial overview within the health technology and biotechnology sectors. It also includes general disclaimers about market d

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 11:12
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Larimar Therapeutics, Inc. – LS:A2P5PP

This article provides access to the enterprise value to EBIT forward data for Larimar Therapeutics, Inc. (LS:A2P5PP) on the TradingView platform. It highlights that the market was closed at the time of access and no trades were recorded. The financial data is provided by ICE Data

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 07:39
Source
TradingView
StocksToTrade Direct company coverage

LRMR Stock Dips As Traders Weigh Cash Runway And Volatility

Larimar Therapeutics Inc. (LRMR) stock fell by 15.16% due to concerns over clinical trial and regulatory updates, closing around $3.11 after an intraday high of $4.30. Despite a strong cash position of $178.5 million, the biotech firm is burning significant cash on R&D, making it

Tone
Negative 29/100
Event
Regulatory and legal
Published
29 Jun 2026 18:10
Source
StocksToTrade
Stock Titan Direct company coverage

Larimar says FDA can review nomlabofusp for accelerated approval

Larimar Therapeutics (LRMR) has submitted the first module of a rolling Biologics License Application (BLA) for accelerated FDA approval of nomlabofusp, a treatment for Friedreich’s ataxia. The FDA noted that existing data, including sustained increases in skin frataxin (FXN) lev

Tone
Neutral 50/100
Event
Regulatory and legal
Published
29 Jun 2026 16:40
Source
Stock Titan
Benzinga Direct company coverage

Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug

Larimar Therapeutics' stock fell by 15% despite the FDA backing a rolling Biologics License Application (BLA) submission for nomlabofusp, its rare disease drug for Friedreich's ataxia. The FDA indicated that existing data appears capable of supporting the BLA and agreed to consid

Tone
Negative 39/100
Event
Market update
Published
29 Jun 2026 14:09
Source
Benzinga
www.marketscreener.com Direct company coverage

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) added to Russell Microcap Growth Benchmark Index

Larimar Therapeutics, Inc. (NasdaqGM:LRMR) has been added to the Russell Microcap Growth Benchmark Index. This news follows several other index-related adjustments for the company and other significant corporate updates, including filing the first module of its Biologics License

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 11:43
Source
www.marketscreener.com
grafa.com Direct company coverage

Larimar Therapeutics submits first module of rolling BLA for nomlabofusp in Friedreich’s ataxia

Larimar Therapeutics has submitted the first module of a rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp, a treatment for Friedreich’s ataxia. The company expects to submit the remaining BLA modules in the second half of 2026. Open-l

Tone
Positive 73/100
Event
Guidance
Published
29 Jun 2026 10:53
Source
grafa.com